Query the real-time market situation of the stock, uncover in-depth data on fund flow, and enter Shanghai Laishi Bar. Shanghai Laishi Fund Flow Related Stocks

Yongshun Biotechnology (0.000%) Ternary Gene (0.000%) Kangle Defender (0.000%) Oukang Pharmaceutical (0.000%)
Related sections
Biological products (0.00%) Standard&Poor's (0.00%) FTSE Russell (0.00%) In vitro diagnostics (0.00%)

The first step in stock trading is to open a stock account

On the evening of December 22nd, Qingdao Haier Biomedical Co., Ltd. ("Haier Biotech", 688139. SH) issued a suspension notice regarding the planning of a major asset restructuring. According to the announcement, Haier Biology and Shanghai Laishi Blood Products Co., Ltd. ("Shanghai Laishi", 002252. SZ) are both listed companies controlled by Haier Group. The two parties have signed an "Absorption and Merger Intention Agreement", in which Haier Biology will absorb and merge Shanghai Laishi by issuing A-shares to all shareholders of Shanghai Laishi, and raise matching funds through the issuance of A-shares. Haier Biotech plans to suspend trading starting from December 23, 2024, with an expected suspension period of no more than 10 trading days.

As the first listed company incubated by Haier Group's innovation strategy in the health sector, Haier Biotech has achieved a good development trend in the field of life sciences. As a surviving company, Haier Biotechnology will further leverage synergies and create a first-class comprehensive biotechnology leading enterprise with sustainable growth potential, rooted locally and facing the world through continuous technological innovation and strategic expansion.

The announcement states that during the planning period of this transaction, both parties will fully consider and effectively protect the legitimate rights and interests of investors, especially small and medium-sized investors, of the listed companies of both parties. During the suspension period, the company will actively promote various work and strictly fulfill its information disclosure obligations in accordance with relevant laws and regulations based on the progress of the matter. After the relevant matters are confirmed, the company will promptly issue relevant announcements and apply for the resumption of stock trading.

In addition, the announcement stated that the specific transaction plan, stock exchange price, debt and credit processing, employee placement, and protection mechanism for dissenting shareholders of this transaction will be agreed upon in the officially signed transaction agreement after communication, argumentation, and negotiation between the two parties.

According to public information, Haier Biotech and Shanghai Laishi are both listed companies under the Haier Group's big health industry "Yingkang Yisheng".

Haier Biotech was listed on the Science and Technology Innovation Board in 2019. Its main business is focused on the fields of life sciences and medical innovation, providing comprehensive solutions for digital scenarios such as smart laboratories, digital hospitals, and smart blood use. Its products and solutions have been applied in more than 150 countries and regions worldwide. Haier Biotechnology has outstanding innovation capabilities and has accumulated 1541 patents.

Shanghai Laishi was listed on the Shenzhen Stock Exchange in 2008 and is a leading blood product manufacturer in China. Its products cover three major categories: albumin, immunoglobulin, and coagulation factors. At the same time, Shanghai Laishi actively explores research and development in other fields of biomedicine, including the development of recombinant protein drugs.

Industry insiders interpret that Haier Biotech and Shanghai Laishi not only belong to the same controller, but also have many synergies in the industry, including strategic planning, product research and development, market network, cost management, overseas expansion, etc. Integrating two listed companies in the fields of life sciences and biopharmaceuticals, Yingkang Life's longer-term strategic goal should be to create a biotechnology industry flagship with sustainable growth potential and international competitiveness through complementary advantages, deep integration, and leveraging economies of scale. If this transaction can be completed, it will also become a landmark case of accelerating the integration of mergers and acquisitions in the industry under the guidance of the "Six Measures for Mergers and Acquisitions" and the "Eight Measures for the Science and Technology Innovation Board".